AI
BCTX

Atom Investors’s Briacell Therapeutics BCTX Stock Holding History

Atom Investors’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-73
Closed -$64.2K – 578
2023
Q4 		$64.2K Buy
+73
New +$52.4K 0.01% 431

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Atom Investors's BCTX Position: Q1 2024 in Review

Atom Investors sold out of Briacell Therapeutics (BCTX) in Q1 2024, closing a stake of 73 shares — an estimated $64.2K sold.

Atom Investors first reported a position in BCTX in Q4 2023 and held it in 1 quarter. The position peaked at $64.2K in Q4 2023. 19 funds tracked by Wall St. Rank hold BCTX as of Q1 2024.

  • Atom Investors reported no remaining Briacell Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Atom Investors sold 73 Briacell Therapeutics shares in Q1 2024, an estimated $64.2K.
  • Atom Investors first reported a position in Briacell Therapeutics in Q4 2023 and held it in 1 quarter.
  • Atom Investors's Briacell Therapeutics position peaked at $64.2K in Q4 2023.
  • 19 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2024.

Based on Atom Investors's 13F filing for Q1 2024, filed 15 May 2024.